Study Shows Nivolumab-Chemo Combination Improves Survival in Gastric and Esophageal Cancers
Categories
Bristol Myers Squibb announced that their phase 3 CheckMate-649 trial demonstrated superior overall survival and profession-free survival using nivolumab plus chemotherapy to treat patients with gastric and esophageal cancers.